Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MINT: Risk-Directed Post-Operative Adjuvant Therapy for HPV-Related OPSCC
NCT03621696Phase 2Completed
- Sponsor
- Washington University School of Medicine
- Start
- Oct 2018
- Primary completion
- Mar 2021
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of Cisplatin micelle injection (HA132) in oropharyngeal squamous cell carcinoma (OPSCC) (3 arms), sponsored by Washington University School of Medicine. Primary endpoint: Mean Percent Weight Change at 4 weeks. Started Oct 2018; status: completed.
02
Drugs
Cisplatin micelle injection (HA132)
03
Conditions
oropharyngeal squamous cell carcinoma (OPSCC)
Beyond the preview
Go deeper on NCT03621696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03621696.